Profile
Dr. Matthew Davidson is a Director & Chief Development Officer at Adial Pharmaceuticals, Inc. He is on the Board of Directors at Adial Pharmaceuticals, Inc. Dr. Davidson was previously employed as a President, CEO, CFO & Director by Azora Therapeutics, Inc. and a Chief Scientific Officer & Director by Verrica Pharmaceuticals, Inc. He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from Stanford University School of Medicine.
Matthew Davidson active positions
| Companies | Position | Start |
|---|---|---|
| ADIAL PHARMACEUTICALS, INC. | Director/Board Member | 2026-06-10 |
Azora Therapeutics, Inc.
Azora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops treatments for inflammatory diseases | Chief Executive Officer | 2019-02-28 |
Former positions of Matthew Davidson
| Companies | Position | End |
|---|---|---|
| VERRICA PHARMACEUTICALS INC. | Founder | - |
Training of Matthew Davidson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medications to treat addiction and related disorders | Health Technology |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University School of Medicine
Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verrica Pharmaceuticals, Inc.
Verrica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Azora Therapeutics, Inc.
Azora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops treatments for inflammatory diseases | Health Technology |
- Stock Market
- Insiders
- Matthew Davidson
















